Insilico Medicines has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115 million upfront payment. The agreement – which could be worth as much ...

Japanese pharma group Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based drug candidate for post-traumatic stress disorder (PTSD) and other psychiatric conditions for $700 million ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

Merck KGaA has teamed up with Flagship Pioneering's Valo Health on an ambitious project to apply AI to the discovery of novel drug targets and therapeutics for Parkinson's disease. The partnership ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type ...

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease ...

With the ink barely dry on one takeover agreement, Novartis has signed another, promising to pay up to $2 billion to acquire ...

The data reveal from the phase 1 INLIGHT study of WVE-007 – an oligonucleotide-based gene-silencing drug designed to switch ...

We are witnessing a long-awaited transformation in depression care. After decades of incremental change, new therapeutic ...

"Screening is typically recommended for patients with confirmed liver cirrhosis or severe liver disease, since many cases of ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...